If you watched to my last content about the (not yet officially announced) new CEO at MusclePharm, I unfortunately had to leave you on this sort of cliffhanger. While I was alerted about the MusclePharm intellectual property (IP) portfolio sale a few days before that content was published, it wasn’t my place to break that news publicly and I provided my reasoning for that to stay transparent with my audience. But this content will get the important stuff, such as why MusclePharm is selling a collection of its intellectual property, what IP was up for sale, and what are some paths for MusclePharm after this public auction. Additionally, I'll explain the accounting issues that are making those possible paths unpredictable. Despite the unknowns severely outweighing the limited public information available, I take a shot in the dark on where I think things could go…(1) bankruptcy (2) bolt-on acquisition or vertical integration M&A move provides strategic value (3) private equity or investment firm buys and simply lease back the IP to MusclePharm, collects payments, and let the new CEO Eric Hillman operate without interference. All I know is a "Part 3" is likely going to be needed soon!

FOLLOW ME ON MY SOCIAL MEDIA ACCOUNTS